Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDXS Codexis	$2.81 -8.5%	$2.48	$1.90 ▼ $6.08	$254.33M	2.52	752,260 shs	999,627 shs
GERN Geron	$1.26 -6.0%	$1.43	$1.17 ▼ $5.06	$853.47M	0.64	11.21 million shs	7.38 million shs
MYGN Myriad Genetics	$5.00 -4.2%	$4.81	$3.81 ▼ $29.30	$481.17M	1.91	1.27 million shs	1.65 million shs
RGLS Regulus Therapeutics	$8.16	$8.05	$0.83 ▼ $8.35	$564.92M	0.35	1.00 million shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDXS Codexis	-8.47%	+5.24%	+26.01%	+32.55%	-14.07%
GERN Geron	-5.97%	-9.35%	-16.56%	+1.61%	-74.29%
MYGN Myriad Genetics	-4.21%	-9.91%	-0.60%	-36.79%	-81.23%
RGLS Regulus Therapeutics	0.00%	0.00%	+0.62%	+320.62%	+368.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDXS Codexis	3.4532 of 5 stars	3.3	1.0	2.5	2.7	1.7	0.6
GERN Geron	3.4127 of 5 stars	3.3	2.0	1.3	2.7	1.7	0.6
MYGN Myriad Genetics	4.5775 of 5 stars	4.1	4.0	4.1	2.5	1.7	0.6
RGLS Regulus Therapeutics	1.6356 of 5 stars	2.1	5.0	0.0	0.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDXS Codexis	2.50	Moderate Buy	$11.00	291.46% Upside
GERN Geron	2.60	Moderate Buy	$4.61	265.96% Upside
MYGN Myriad Genetics	2.13	Hold	$14.38	187.69% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside

Current Analyst Ratings Breakdown

Latest CDXS, GERN, RGLS, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$1.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/8/2025	GERN Geron	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$4.00 ➝ $1.50
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00
5/7/2025	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$22.00 ➝ $6.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDXS Codexis	$59.35M	3.92	N/A	N/A	$0.82 per share	3.43
GERN Geron	$76.99M	10.42	N/A	N/A	$0.46 per share	2.74
MYGN Myriad Genetics	$837.60M	0.55	$0.96 per share	5.22	$7.70 per share	0.65
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDXS Codexis	-$65.28M	-$0.99	N/A	N/A	N/A	-149.47%	-118.47%	-53.37%	8/6/2025 (Estimated)
GERN Geron	-$174.57M	-$0.21	N/A	N/A	N/A	-119.54%	-47.86%	-26.78%	8/6/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)

Latest CDXS, GERN, RGLS, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MYGN Myriad Genetics	-$0.02	N/A	N/A	N/A	$202.30 million	N/A
5/14/2025	Q1 2025	CDXS Codexis	-$0.20	-$0.25	-$0.05	-$0.25	$10.38 million	$7.54 million
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
5/7/2025	Q1 2025	GERN Geron	-$0.04	-$0.03	+$0.01	-$0.03	$49.88 million	$39.60 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDXS Codexis	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDXS Codexis	0.59	3.72	3.64
GERN Geron	0.44	7.87	6.97
MYGN Myriad Genetics	0.08	1.90	1.71
RGLS Regulus Therapeutics	N/A	16.31	16.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDXS Codexis	78.54%
GERN Geron	73.71%
MYGN Myriad Genetics	99.02%
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
CDXS Codexis	2.10%
GERN Geron	7.42%
MYGN Myriad Genetics	2.10%
RGLS Regulus Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDXS Codexis	250	82.85 million	81.11 million	Optionable
GERN Geron	70	636.92 million	589.66 million	Optionable
MYGN Myriad Genetics	2,700	92.18 million	90.24 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable

CDXS, GERN, RGLS, and MYGN Headlines

Recent News About These Companies

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

June 28, 2025 | finance.yahoo.com

Regulus Therapeutics (NASDAQ:RGLS) Upgraded at Wall Street Zen

June 27, 2025 | marketbeat.com

Novartis concludes acquisition of Regulus Therapeutics

June 26, 2025 | medicaldialogues.inM

Novartis concludes Regulus Therapeutics acquisition

June 26, 2025 | pharmaceutical-technology.comP

Press Release: Novartis completes acquisition of Regulus Therapeutics

June 25, 2025 | finanzen.atF

Novartis completes acquisition of Regulus Therapeutics

June 25, 2025 | globenewswire.com

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

June 24, 2025 | pharmabiz.comP

Regulus Therapeutics Inc.

June 21, 2025 | barrons.com

Regulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase - What's Next?

June 20, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Hold" from Analysts

June 19, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

June 18, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 Shares

June 5, 2025 | insidertrades.com

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)

June 4, 2025 | gurufocus.com

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout

June 4, 2025 | seekingalpha.com

Novartis commences tender offer to acquire Regulus Therapeutics

May 29, 2025 | pharmabiz.comP

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows

May 29, 2025 | fiercepharma.comF

Novartis arm commences tender offer to buy Regulus Therapeutics

May 28, 2025 | medicaldialogues.inM

Latham and Covington Advise on Novartis’s Acquisition of Regulus

May 16, 2025 | lawstreetmedia.comL

Regulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 9, 2025 | finanznachrichten.de

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025 | prnewswire.com

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

May 4, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS, GERN, RGLS, and MYGN Company Descriptions

Codexis NASDAQ:CDXS

$2.81 -0.26 (-8.47%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.01 (+0.36%)

As of 08:25 AM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Geron NASDAQ:GERN

$1.26 -0.08 (-5.97%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.28 +0.02 (+1.59%)

As of 08:26 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Myriad Genetics NASDAQ:MYGN

$5.00 -0.22 (-4.21%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$5.05 +0.05 (+1.00%)

As of 08:02 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time